Skip to main content

Search

COVID-19 UPDATES >

Welcome to Janssen Belgium

Visit Janssen Global

As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities

As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities

COVID-19 Coronavirus Infections

Title

Covid19

Our innovative vaccine technology platform - AdVac® - offers hope for accelerated vaccine development. Janssen's AdVac® vectors are based on a specific type of adenovirus. This type of adenovirus has been genetically modified so that it can no longer multiply in humans and cannot cause disease. Because of this they are relatively harmless, and these viruses can be well used to induce desired immune responses in the human body. Want to know more about our AdVac® technology? Watch the video and read more here.

For COVID-19 related press questions,click here.

For COVID-19 vaccine information

Please use the contact details below:
Phone: +32 3 393 93 23
E-mail: [email protected] www.covid19vaccinejanssen.com

WHAT IS THE RESPONSE OF JANSSEN TO THE COVID-19 PANDEMIC?

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Substantial Protection of Single-Shot COVID-19 Vaccine in the U.S.

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Johnson & Johnson Announces Initiation of Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with the European Medicines Agency

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

Our scientists are screening thousands of molecules to
find a cure for COVID-19

We contribute to
COVID-19 tests in Belgium

We produced desinfectant hand liquid to address
hospital shortages in the fight against the coronavirus

In addition to our core tasks, we offer our employees the opportunity to volunteer

Janssen co-leader
of CARE consortium

Janssen Vaccine Technology

WHAT IMPACT DOES COVID-19 HAVE ON US AS A COMPANY?

With the Johnson & Johnson family, we’ve worked out a robust business continuity plan
to keep our business going

Latest press releases

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Substantial Protection of Single-Shot COVID-19 Vaccine in the U.S.

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Johnson & Johnson Announces Initiation of Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with the European Medicines Agency

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

Johnson & Johnson Resumes all Clinical Trials of its Janssen COVID-19 Vaccine Candidate in Europe

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use